Phoenix Overseas (PHOGLOBAL)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Promoter holding is high at 70.95%, aligning management with minority shareholders.
• Sales growth of 18.59% shows the business is expanding its top line.
• Dividend yield of 3.17% offers some income support if sustained.
• ROCE of 11.36% is reasonable for a trading/distribution operation.

Concerns

• Latest quarter net loss of ₹1 Cr on ₹239 Cr sales shows razor-thin/negative margins.
• Profit growth of -200.84% and Piotroski F-Score of 4/9 indicate deteriorating fundamentals.
• P/E of 16.69 is not cheap for a small distributor with collapsing earnings; PEG 0.90 is misleading.
• Missing book value, ROE, and debt/equity data limits the margin-of-safety analysis.

AI Analysis

At first glance, Phoenix Overseas looks like a small, unexciting trading business. In my world, distribution is a tough way to make a durable rupee: you're a price-taker, customers can switch, and success depends on working capital and volume rather than a moat. The figures confirm this. The latest quarter shows ₹239 crore of sales, yet net profit is minus ₹1 crore. That's a hair-thin margin and a warning that the business has no pricing power. Reported profit growth of -200.84% is alarming, and the Piotroski F-score of 4/9 suggests the financial health has deteriorated. A P/E of 16.69 might look moderate, but paying 16.7 times earnings for a trader whose profits are collapsing is not my idea of margin of safety. The PEG of 0.90 appears attractive only if you naively use sales growth; earnings are going the wrong way. On the positive side, promoter holding is 70.95%, which at least ties owners to minority shareholders. The 3.17% dividend yield provides some cash return, but I would question whether it is safe if losses continue. ROCE of 11.36% is okay, but for a distributor it is not extraordinary. I also have no book value, ROE, or debt-to-equity data; in Graham's language, inadequate information demands a larger discount. This is not a compounder. It may be a cyclical or turnaround situation, but there is not enough evidence of a durable recovery. I would wait on the sidelines until profitability returns and the company demonstrates that its sales growth can translate into consistent earnings.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer